Information Provided By: 
Fly News Breaks for December 7, 2015
TGTX
Dec 7, 2015 | 09:27 EDT
Roth Capital analyst Joseph Pantginis said TG Therapeutics' update at the ASH meeting was "strong" and that he continues to be impressed by both the efficacy and safety profile of the company's two lead drugs. The analyst keeps a Buy rating and $33 price target on the stock, which is a Focus Pick of the firm.
News For TGTX From the Last 2 Days
There are no results for your query TGTX
